The potential efficacy of GABAB antagonists in depression

Curr Opin Pharmacol. 2017 Aug:35:101-104. doi: 10.1016/j.coph.2017.07.009. Epub 2017 Aug 11.

Abstract

Evidence for the potential utility of GABAB antagonists has been assembled from a variety of sources, including clinical experience with the GABAB agonist baclofen, murine genetic GABAB knock-outs, rodent studies of GABAB receptor expression and function following treatment with antidepressant therapies, animal models of depression, and some functional and post mortem data from human subjects. Definitive testing of GABAB antagonists in depression, however, still awaits the development of potent, selective and brain-penetrant compounds for human testing.

Publication types

  • Review

MeSH terms

  • Animals
  • Depression / drug therapy*
  • Depression / metabolism
  • GABA-B Receptor Antagonists / therapeutic use*
  • Humans
  • Receptors, GABA-B / metabolism
  • Treatment Outcome

Substances

  • GABA-B Receptor Antagonists
  • Receptors, GABA-B